The Exploration of Chemokines Importance in the Pathogenesis and Development of Endometrial Cancer.
Jakub DobrochKlaudia BojczukAdrian KołakowskiMarta BaczewskaPaweł KnappPublished in: Molecules (Basel, Switzerland) (2022)
Endometrial cancer (EC) is one of the most frequent female malignancies. Because of a characteristic symptom, vaginal bleeding, EC is often diagnosed in an early stage. Despite that, some EC cases present an atypical course with rapid progression and poor prognosis. There have been multiple studies conducted on molecular profiling of EC in order to improve diagnostics and introduce personalized treatment. Chemokines-a protein family that contributes to inflammatory processes that may promote carcinogenesis-constitute an area of interest. Some chemokines and their receptors present alterations in expression in tumor microenvironment. CXCL12, which binds the receptors CXCR4 and CXCR7, is known for its impact on neoplastic cell proliferation, neovascularization and promotion of epidermal-mesenchymal transition. The CCL2-CCR2 axis additionally plays a pivotal role in EC with mutations in the LKB1 gene and activates tumor-associated macrophages. CCL20 and CCR6 are influenced by the RANK/RANKL pathway and alter the function of lymphocytes and dendritic cells. Another axis, CXCL10-CXCR3, affects the function of NK-cells and, interestingly, presents different roles in various types of tumors. This review article consists of analysis of studies that included the roles of the aforementioned chemokines in EC pathogenesis. Alterations in chemokine expression are described, and possible applications of drugs targeting chemokines are reviewed.
Keyphrases
- poor prognosis
- endometrial cancer
- dendritic cells
- long non coding rna
- early stage
- cell proliferation
- nk cells
- regulatory t cells
- bone marrow
- cell migration
- oxidative stress
- immune response
- stem cells
- squamous cell carcinoma
- liver injury
- vascular endothelial growth factor
- cancer therapy
- copy number
- drug delivery
- endothelial cells
- inflammatory response
- neoadjuvant chemotherapy
- combination therapy
- loop mediated isothermal amplification
- rectal cancer